This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Regeneron, Roche to Distribute Antibody Cocktail for Coronavirus
by Zacks Equity Research
Regeneron (REGN) teams up with Roche to develop and distribute REGN-COV2, its experimental dual antibody cocktail for the prevention and treatment of COVID-19.
Biotech Stock Roundup: GILD Gets CRL, REGN Collaborates With RHHBY & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
The Zacks Analyst Blog Highlights: Analog Devices, General Motors, QUALCOMM, Regeneron Pharmaceuticals and Lam Research
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Analog Devices, General Motors, QUALCOMM, Regeneron Pharmaceuticals and Lam Research
Sanofi to Buy Immunology Firm Principia Biopharma for $3.7B
by Zacks Equity Research
Sanofi (SNY) offers $3.68 billion to buy Principia Biopharma. The deal is likely to strengthen the company's core R&D areas of autoimmune and allergic diseases.
S&P 500 Sees Best 100-Day Gain Since 1933: 5 Winners
by Tirthankar Chakraborty
With the S&P 500 notching its best 100-trading day gain since 1933, it will be wise to invest in stocks listed on the index that have not only gained in the said period but also have more upside left.
Regeneron's BLA for Cholesterol Drug Accepted by the FDA
by Zacks Equity Research
The FDA accepts Regeneron's (REGN) application for evinacumab in HoFH, with priority review.
5 Top-Ranked Stocks Driving ETF as S&P 500 Nears New Highs
by Sweta Killa
Though most stocks in the fund's portfolio are in the green this year, we have highlighted five that are leading the way in the ETF and have a Zacks Rank #2, suggesting their continued outperformance.
Biotech Stock Roundup: BMY & REGN Q2 Earnings, Gilead NDA for Coronavirus Drug
by Zacks Equity Research
The biotech sector remains in focus with earnings, regulatory and other pipeline updates.
Is Regeneron Pharmaceuticals (REGN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (REGN) Outperforming Other Medical Stocks This Year?
Drug/Biotech Stock Q2 Earnings Due on Aug 11: VIR and AUPH
by Kinjel Shah
Let us take a look at two small biotech companies, VIR and AUPH, which are gearing up for their earnings release.
Alnylam (ALNY) Beats on Q2 Earnings, Narrows Sales Guidance
by Zacks Equity Research
Alnylam (ALNY) posts a narrower-than-expected loss in the second quarter of 2020 and sales miss estimates.
10 Best-Performing Stocks in Nasdaq ETF as Index Tops 11,000
by Sweta Killa
The latest broad market rally has pushed the tech-heavy Nasdaq Composite Index to new record highs above the 11,000 milestone.
Regeneron's (REGN) Q2 Earnings & Sales Surpass Estimates
by Zacks Equity Research
Regeneron (REGN) beats on Q2 earnings and sales on solid performance of Dupixent and oncology drug, Libtayo.
Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of 14.93% and 9.05%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Drug/Biotech Stock Q2 Earnings on Aug 5: REGN, MRNA & More
by Kinjel Shah
Let us take a look at five drug/biotech companies, REGN, MRNA, SRPT, ACAD and HZNP, which are gearing up for their earnings release.
What's in the Cards for Regeneron's (REGN) Q2 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2020 results.
Regeneron (REGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed at $632.16 in the latest trading session, marking a +0.18% move from the prior day.
Regeneron (REGN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sanofi (SNY) Q2 Earnings Top Estimates, Sales Lag, EPS View Up
by Zacks Equity Research
Sanofi (SNY) beats Q2 estimates for earnings while missing the same for sales. Gain from COVID-19 associated patient stockpiling in the first quarter reverses in this quarter. Stock up.
Sanofi (SNY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Sanofi's (SNY) performance when it reports second-quarter results.
Regeneron (REGN) Stock Moves -1.13%: What You Should Know
by Zacks Equity Research
In the latest trading session, Regeneron (REGN) closed at $630.31, marking a -1.13% move from the previous day.
Regeneron (REGN) Stock Moves -0.8%: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed at $615.88 in the latest trading session, marking a -0.8% move from the prior day.
Gilead Presents Additional Data on Coronavirus Drug Remdesivir
by Zacks Equity Research
Gilead (GILD) announces a comparative analysis of remdesivir, wherein the drug was associated with a 62% reduction in risk of mortality compared to standard of care.
Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE